E-Book Overview
Thirteen chapters by industrial and academic authorities in this rapidly evolving field present detailed case histories and reviews of current sophisticated protein-drug delivery technologies. Highlights include a comprehensive overview of insulin delivery and a discussion of the use of biodegradable microspheres.
E-Book Content
Protein Delivery Physical Systems Pharmaceutical Biotechnology Series Editor: Ronald T. Borchardt The University of Kansas Lawrence, Kansas Recent volumes in this series: Volume 2 Volume 3 Volume 4 Volume 5 Volume 6 Volume 7 Volume 8 Volume 9 Volume 10 STABILITY OF PROTEIN PHARMACEUTICALS, Part A: Chemical and Physical Pathways of Protein Degradation Edited by Tim J. Ahem and Mark C. Manning STABILITY OF PROTEIN PHARMACEUTICALS, Part B: In Vivo Pathways of Degradation and Strategies for Protein Stabilization Edited by Tim J. Ahem and Mark C. Manning BIOLOGICAL BARRIERS TO PROTEIN DELIVERY Edited by Kenneth L. Audus and Thomas J. Raub STABILITY AND CHARACTERIZATION OF PROTEIN AND PEPTIDE DRUGS: Case Histories Edited by Y. John Wang and Rodney Pearlman VACCINE DESIGN: The Subunit and Adjuvant Approach Edited by Michael F. Powell and Mark J. Newman PHYSICAL METHODS TO CHARACTERIZE PHARMACEUTICAL PROTEINS Edited by James N. Herron, Wim Jiskoot, and Daan J. A. Crommelin MODELS FOR ASSESSING DRUG ABSORPTION AND METABOLISM Edited by Ronald T. Borchardt, Philip L. Smith, and Glynn Wilson FORMULATION, CHARACTERIZATION, AND STABILITY OF PROTEIN DRUGS: Case Histories Edited by Rodney Pearlman and Y. John Wang PROTEIN DELIVERY: Physical Systems Edited by Lynda M. Sanders and R. Wayne Hendren A Continuation Order Plan is available for this series. A continuation order will bring delivery of each new volume immediately upon publication. Volumes are billed only upon actual shipment. For further information please contact the publisher. Protein Delivery Physical Systems Edited by Lynda M. Sanders Consultant in Pharmaceutical Development Los Altos, California and R. Wayne Hendren Glaxo Wellcome Research Triangle Park, North Carolina Kluwer Academic Publishers New York, Boston, Dordercht, London, Moscow eBook ISBN: Print ISBN: 0-306-46803-4 0-306-45359-2 ©2002 Kluwer Academic Publishers New York, Boston, Dordrecht, London, Moscow All rights reserved No part of this eBook may be reproduced or transmitted in any form or by any means, electronic, mechanical, recording, or otherwise, without written consent from the Publisher Created in the United States of America Visit Kluwer Online at: and Kluwer's eBookstore at: http://www.kluweronline.com http://www.ebooks.kluweronline.com Contributors Mary Tanya am Ende • Pfizer Central Research, Pharmaceutical Research and Development, Groton, Connecticut 06340 • D. Bommannan Jens Brange • Cygnus,Inc., Redwood City, California 94063 Novo Nordisk A/S, DK-2880 Bagsvaerd, Denmark Ulrike Bremer • Susan M. Cady 1258 • Pharmetrix, Inc., Menlo Park, California 94025 Hoechst Roussel Vet, Somerville, New Jersey 08876- Jeffrey L. Cleland • Pharmaceutical Research & Development, Genentech, Inc., 460 Pt. San Bruno Boulevard, South San Francisco, California94080 S. Mark Cox • Mary D. DiBiase Atrix Laboratories, Inc., Fort Collins, Colorado 80525 • Biogen, Cambridge, Massachusetts 02142 Avi Domb • Department of Pharmaceutical Chemistry, The Hebrew University, Jerusalem, Israel 91120 Richard L. Dunn 80525 • Atrix Laboratories, Inc., Fort Collins, Colorado Ellen G. Duysen 80525 • Atrix Laboratories, Inc., Fort Collins, Colo